Hidradenitis Suppurativa (HS) is a chronic inflammatory skin disorder characterized by the formation of painful abscesses and tunnels beneath the skin. It commonly affects areas where skin folds and rubs together, such as the armpits, groin, buttocks, and under the breasts. The condition often worsens over time and, in severe cases, can lead to significant scarring and a diminished quality of life. Although the exact cause of HS remains unclear, it is thought to be related to an abnormal immune response and is frequently associated with other conditions like Crohn’s disease and metabolic syndrome. Early diagnosis and management are vital to control symptoms and prevent progression of the disease.

Get a snapshot of the 7MM landscape—view the infographic now!: Click Here

Hidradenitis Suppurativa Epidemiological Segmentation
The epidemiological segmentation of Hidradenitis Suppurativa in the 7 major markets (7MM) from 2020 to 2034 includes:

• Total prevalent cases of Hidradenitis Suppurativa in the US
  
• Total diagnosed prevalent cases in the US
  
• Gender-specific cases in the US
  
• Age-specific cases in the US
  
• Stage-specific cases in the US
  
• Treated prevalent cases in the US
  

Hidradenitis Suppurativa Epidemiology
In 2023, Hidradenitis Suppurativa demonstrated the following patterns across the 7MM:

• The total prevalent cases of HS in the 7MM were approximately 6.2 million, with a projected increase by 2034.
  
• The US recorded the highest number of diagnosed cases, with nearly 877,600 cases in 2023.
  
• Among the EU4 countries and the UK, Germany had the largest number of diagnosed cases, whereas Spain had the fewest.
  
• HS was more prevalent in females (~75%) than males (~25%) in the US, EU4, and the UK. In contrast, in Japan, males made up nearly 70% of cases, with females accounting for about 30%.
  
• The highest prevalence in the US was observed in the 30–39 age group, representing nearly 26% of diagnosed cases.
  
• Stage I of the Hurley classification was the most frequent stage, with around 480,000 cases in the US in 2023.
  

Hidradenitis Suppurativa Market
In 2023, the total market value for Hidradenitis Suppurativa across the 7MM was estimated at approximately USD 1.4 billion.

Hidradenitis Suppurativa Market Drivers

• The introduction of novel therapies such as Povorcitinib (INCB054707), Izokibep, and RINVOQ (upadacitinib) provides targeted treatment options, expected to enhance patient outcomes and drive market growth.
  
• Increasing awareness of HS and improvements in diagnostic techniques are likely to promote earlier diagnosis and treatment, expanding the market for HS therapies.

You’ve seen the key stats—now discover what’s driving them: Click Here

Hidradenitis Suppurativa Market Barriers

• The complexity in diagnosing and managing HS due to its variable presentation and progression poses challenges in establishing standardized treatment guidelines and conducting clinical trials.
  
• The high cost of emerging therapies and limited accessibility in certain regions may restrict the widespread adoption of these treatments.
  

Hidradenitis Suppurativa Emerging Therapies

• Povorcitinib (INCB054707)
  
• Izokibep
  
• RINVOQ (upadacitinib)
  
• Lutikizumab (ABT-981)
  
• Sonelokimab (M1095)
  
• Spesolimab
  
• Brepocitinib
  
• Eltrekibart
  
• Ruxolitinib 1.5% Cream
  
• SAR-444656/KT-474
  
• Orismilast
  
• And others
  

Hidradenitis Suppurativa Key Players

• Incyte Corporation
  
• ACELYRIN
  
• AbbVie
  
• MoonLake Immunotherapeutics
  
• Boehringer Ingelheim
  
• Priovant Therapeutics
  
• Eli Lilly
  
• Sanofi
  
• Kymera Therapeutics
  
• UNION Therapeutics
  
• And others